Page 299 - Binder2

• A parent giving their child a capsule over breakfast,
not a shot at the doctor’s office.
• A patient in a rural town accessing complex
biologic therapy without a local specialist.
• An immunocompromised adult managing
maintenance therapy while avoiding clinical
exposure risks.

This isn’t just convenience—it’s capacity. It changes who
can receive biologics, how often, and at what cost to the
system and the individual.

Blurring the Line Between Food and Pharmacy

When a drug grows in a plant and is eaten like a food, the
boundaries between agriculture and pharmaceuticals begin
to dissolve.

This doesn’t mean medicines lose their rigor. It means
delivery adapts to the body’s natural routes of tolerance and
absorption. It also means that the infrastructure we use to
grow crops—indoor farms, hydroponic greenhouses, seed
stock repositories—can now serve dual roles as
pharmaceutical production platforms.

In regions where food security and healthcare access
overlap, this is transformational. A single indoor farming
hub could grow:

• Lettuce expressing insulin peptides for local
diabetics
• Duckweed producing oral antibodies for seasonal
gut infections

297